Durante este congreso, comentaremos los resultados de alguno de los siguientes ensayos clínicos:
DOMINGO, 14 de Noviembre |
The Resynchronization/defibrillation for Ambulatory heart Failure Trial (RAFT) – Optimizing outcomes in mild to moderate HF, is there a role for CRT? |
Evaluation of the HeartWare® HVAD Left Ventricular Assist Device System for the Treatment of Advanced Heart Failure: Results of the ADVANCE Bridge to Transplant Trial – Comparison of survival outcomes based on type of assist device |
Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) – Nesiritide or placebo for improved symptoms and outcomes in acute decompensated HF |
The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality Or Heart Failure Hospitalization In Subjects With Nyha Class Ii Chronic Systolic Heart Failure. Emphasis-hf – Efficacy and safety of elperenone in improving HF |
LUNES, 15 de Noviembre |
Stroke Prevention Using the Oral Direct Factor Xa inhibitor Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation (ROCKET AF) – Rivaroxaban vs. warfarin for stroke prevention in atrial fibrillation |
Primary Results from the SMART AV Trial: A Randomized Trial Comparing Empiric, Echocardiographic Guided and Algorithmic AV Delay Programming in Cardiac Resynchronization Therapy (CRT) – Appraisal of the importance of AV interval optimization on outcomes after implantation of a CRT defibrillator |
Efficacy And Safety Of Prescription Omega-3-Acid Ethyl Esters (P-OM3) For The Prevention Of Recurrent Symptomatic Atrial Fibrillation (AF) – Emerging evidence regarding the role of omega-3-acid ethyl ester in AF |
CLOSURE I: A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients with a Stroke or Transient Ischemic Attack due to Presumed Paradoxical Embolism through a Patent Foramen Ovale – First randomized controlled trial results to guide PFO treatment |
MARTES, 16 de Noviembre |
Standard Versus High-Dose Clopidogrel According to Platelet Function Testing After PCI: Results of the GRAVITAS Trial – Achieving effective clopidogrel dose response to reduce CV events post PCI |
NV1FGF Gene Therapy on Amputation-Free Survival in Critical Limb Ischemia – Phase 3 Randomized Double-Blind Placebo-Controlled Trial – International study examining the role of gene therapy and amputation-free survival |
Late Cardiac Death And Myocardial Infarction Associated With Late Stent Thrombosis In Large Vessel Stenting After 1st Or 2nd Generation Drug-eluting Compared To Bare-metal Stents: the BASKET PROspective Evaluation Examination (BASKET PROVE) – The evolution of drug-eluting stent technology, is newer better? |
Acetylcystein for the Prevention of Contrast-Induced nephropaThy (ACT) Trial: a Pragmatic Multicenter Randomized Trial to Evaluate the Efficacy of Acetylcysteine for the Prevention of Renal Outcomes in Patients Undergoing Coronary and Vascular Angiography – The role of acetylcysteine in preventing contrast-induced nephropathy |
MIERCOLES, 17 de Noviembre |
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): Testing C-Reactive Protein at baseline and on-treatment as an independent predictor of cardiovascular outcomes – Evaluation of high sensitivity C-reactive protein as an independent predictor of cardiovascular events |
Primary Results of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib – Efficacy and safety of cholesteryl ester transfer protein inhibition using anacetrapib in CHD |
Results of the First Major Clinical Trial of An Oral Agent Inducing Apo A1 Synthesis: A New Approach to HDL Raising and CV Risk Modification – Efficacy and safety of the first oral therapy to raise apoA1 levels in patients with heart disease |
Symplicity HTN-2: International, Multicenter, Prospective, Randomized, Controlled Trial Of Endovascular Selective Renal Sympathetic Denervation For The Treatment Of Hypertension – Test of endovascular ablation of the renal sympathetic nerves as a safe and effective treatment for uncontrolled hypertension |